Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

B
Bert O'Neil, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.

Description

The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumor
  • Age: Between 18 Years - 100 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1105005289

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center